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INTRODUCTION 
 
 
1. Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It represents 
the sixth most frequent solid tumor worldwide, with more than half a million new cases per 
year, and the third cause of cancer-related death (Ferlay J. et al. 2010). Chronic liver disease 
and cirrhosis are the main causes of HCC in association with major risk factors including 
hepatitis B (HBV) and hepatitis C (HCV) viruses, alcohol consumption and toxic exposures to 
aflatoxin B1. Although less frequent, other risk factors include nonalcoholic fatty liver 
disease (Hashimoto E et al, 2004), diabetes (El-Serag HB et al, 2004; Regimbeau J et al, 
2004), hereditary hemochromatosis (Hellerbrand C et al, 2003), obesity (Regimbeau J et al, 
2004) and oral contraceptives (Maheshwari S et al, 2007). 
 
1.1. Epidemiology 
The heterogenous worldwide incidence of HCC reflects variations in distribution and in 
the natural history of HBV and HCV infections. More than 80% of cases arise in sub-Saharan 
Africa and in Eastern Asia; China alone accounts for more than 50% of the world’s cases (El-
Serag HB. et al. 2007). In these areas HBV is highly prevalent except Japan where HCV is the 
leading cause (Gao J. et al. 2012). North-America and Europe are considered areas with low 
incidence rates even if some data indicate a steadily increasing in the West (Parkin DM et al, 
2001) where HCV plays a more dominant role.  
Moreover, the incidence rate of HCC may vary by ethnicity. In the Unites States, for 
example, HCC incidence is two times higher in Asians than in African Americans, whose rates 
are two times higher than in whites (El-Serag HB. et al. 2007). 
A higher HCC incidence is also observed in males, with male to female ratio being 
estimated approximately between 2:1 and 4:1. This divergence can be explained by sex-
specific differences in exposure to different risk factors such as HBV and HCV infection and 
alcohol consumption. In addition, an experimental study has shown in male mice a two to 
eight fold increase in the development of HCC, supporting the hypothesis that androgens 
may influence HCC progression. (Rudolph KL et al, 2000). Worldwide, in almost all areas, the 
peak of higher incidence is observed in males earlier in life than females, with female rates 
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peaking in the age group 5 years older than the peak age group for males (El-Serag HB. et al. 
2007). 
 
1.2. Risk factors 
HBV is the most frequent risk factor for HCC, with more than 240 million people with chronic 
infection worldwide (WHO Media centre, 2014). The relationship between HCC and HBV is well-
established from the early eighties even if the role of HBV in the malignant transformation 
remains unclear.  
In this regard, different mechanisms have been proposed. The chronic HBV infection 
causes a continuous immune-mediated destruction of infected hepatocytes, resulting in 
hepatocytes proliferation and liver regeneration (Guidotti LG et al, 2006; Seeger C et al, 
2007). 
The persistent inflammation, the recruitment of immune cells, and the consequent 
local increase in inflammatory cytokines can produce a locally mutagenic microenvironment; 
in addition, an excessive amount of reactive oxygen species (ROS) can directly mediate 
mutagenic processes by damaging DNA. Furthermore, the increase of inflammatory 
cytokines may induce several signalling pathways involved in gene transcription, cell 
proliferation, or cell survival (Berasain C et al, 2009). 
Moreover, several studies have shown that HBV viral DNA can integrate into the host 
genome and that it actually occurs in the infected livers since the early stages of natural 
acute infections. Multiple integrations events have been detected in chronic hepatitis 
tissues, and integrated HBV sequences have been seen in 80%-90% of HBV-related HCCs 
(Balsano C et al, 1994). Genome integration of HBV at specific sites has been associated with 
major genetic alterations, including generalized genomic instability, gene and chromosomal 
deletions and translocations, amplification of cellular DNA, and generation of fusion 
transcripts (Reifenberg K et al, 1999; Klein N et al, 1999). 
The third mechanism by which HBV contributes to carcinogenesis is by expression of 
viral proteins, in particular, X protein (HBx). Although HBx does not bind directly to DNA, in 
the cytoplasm it modulates mitogenic signaling pathways involved in oncogenesis, 
proliferation, apoptosis, inflammation and immune response. In the nucleus it promotes the 
interaction with numerous transcription factors modulating gene expression (Bouchard MJ 
and Navas-Martin S., 2011). 
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Twenty years after the discovery of HBV, Choo and colleagues in 1989 identified 
hepatitis C virus (Choo QL et al, 1989), an enveloped, single stranded, positive sense RNA 
virus (Hoofnagle et al, 1999). HCV is the major risk factor in areas with low prevalence of 
HBV; the infection is present in about 3% of world’s population and 170 million people are 
chronic carriers (Gao J et al, 2012). 
The mechanism by which HCV causes HCC is not well defined. Unlike HBV, it does not 
integrate into the human genome. The main hypothesis is that in the context of chronic liver 
damage caused by HCV infection, with a persistent inflammation and hepatocyte 
regeneration, the resultant cirrhosis can lead to chromosomal damage that can trigger the 
development of HCC in the modified tissue microenvironment (Gomaa AI et al, 2008). 
Oxidative stress, steatosis and insulin resistance have been identified as procarcinogenic 
cofactors in chronic HCV infections (McGivern DR et al, 2009). 
A second hypothesis is that interactions between host and viral proteins may have a 
direct role in HCV-related HCC through the modulation of cellular proliferation, apoptosis 
and immunological responses (Pang R et al, 2005). In fact HCV core and non-structural 
proteins can modulate several tumor suppressor genes and their targets and activate 
different intracellular pathways. HCV core protein has been found to bind to p53 (Ray RB et 
al, 1997), p73 (Alisi A et al, 2003) and pRb (Cho J et al, 2001). In particular, core and non-
structural proteins can modulate cell-cycle control by regulating the cyclin-dependent 
inhibitor p21/Waf, a target of p53 (Uchida M et al, 2002). 
Various studies have shown the role of core proteins in the regulation of three 
different pathways involved in cell proliferation. Viral proteins can activate the Raf1/MAPK 
thus promoting cell proliferation (Hayashi J et al, 2000) and the Wnt/β-catenin pathway, 
which can control DNA synthesis and cell-cycle progression (Fukutomi T et al, 2005). Core 
proteins modulate also TGFβ signaling, which is involved in cell proliferation, apoptosis, and 
differentiation (Shin JY et al, 2005). 
The association between heavy and prolonged alcohol consumption (more than 50-70 
g/day) with both HCC incidence and mortality was found in the mid eighties (Nanji AA et al, 
1985). Alcohol ingestion can lead to the development of HCC through several mechanisms: 
as a carcinogen, leading to the development of cirrhosis, and with a synergistic effect with 
other risk factors, such as HBV and HCV (Gao J et al, 2012). Some data demonstrated that 
among consumers of alcohol, the risk of developing HCC increases linearly with a daily intake 
of more than 60 grams; the simultaneous presence of HCV infection increases about 2-fold 
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the risk of hepatocellular carcinoma development (Donato F et al, 2002). Other studies 
confirmed the interaction between alcohol assumption and risk factors like diabetes, obesity 
and smoking (Wang LY et al, 2003; Yuan JM et al, 2004; Singal AK et al, 2007; Chuang SC et 
al, 2009). 
Aflatoxins are mycotoxins produced by Aspergillus parasiticus and Aspergillus Flavus. 
Under favourable conditions, like warm and damp environment, these fungi grow and 
colonize many types of foods such as grain, corn and peanuts. In particular, Aflatoxin B1 
(AFB1) was classified as group I carcinogen by the International Agency for Research on 
Cancer (IARC, 1987). After ingestion, AFB1 requires metabolic conversion to its active 
intermediate, AFB1-exo-8,9-epoxide, in order to bind DNA and cause damage (Garner RC et 
al, 1972). In particular, a G>T mutation of the p53 gene at codon 249 has been associated 
with AFB1 exposure; this mutational inactivation has been observed in 30%-60% of HCC 
developed in geographical areas that are endemic for AFB1 (Bressac B et al, 1991; Turner PC 
et al, 2002). Several authors have demonstrated an association between AFB1 exposure and 
HBV infection (Yeh FS et al, 1989; Qian GS et al, 1994) and that the interaction of both risk 
factors increased the risk of hepatocarcinogenesis by interfering with the ability of 
hepatocytes to metabolize aflatoxins (Smela ME et al, 2001; Williams JH. et al. 2004). 
The investigation of different mechanisms leading to hepatocarcinogenesis points to 
common pathogenetic pathways and processes involving, in particular, p53 inactivation or 
mutation, inflammation, continuous cycles of necrosis and regeneration, and oxidative 
stress, underlying their essential contribute in HCC development (Farazi PA et al, 2006). 
 
1.3. Molecular mechanisms 
As described above, many studies over the years have identified major risk factors for 
HCC, even if little is known about the molecular mechanisms that contribute to HCC 
development.  
Growing evidence suggests that gradual accumulation of mutations and genetic 
changes in preneoplastic hepatocytes cause malignant transformation leading to HCC 
development (El-Serag et al, 2007). 
The neoplastic evolution of HCC is a multi-step process (Farazi PA et al, 2006). Different 
etiologic agents (hepatitis virus infection, toxins, alcohol, etc.) are able to induce hepatic 
injury followed by necrosis and hepatocyte regeneration; this setting of chronic liver disease 
can then progress to cirrhosis, a predisposing condition to hepatocarcinogenesis, which 
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becomes manifest after 20-40 years of latency (El-Serag HB et al, 2007). The cirrhosis process 
is characterized by the formation of abnormal liver nodules surrounded by collagen 
deposition and scar tissue. Afterwards, the first step towards HCC is the formation of 
hyperplastic nodules of regenerating hepatocytes followed by the appearance of dysplastic 
nodules. The latter pre-malignant lesions consist of abnormal liver architecture with an 
increase in trabecular thickening and including clear cells, enriched in glycogen or lipids 
deposits, and nuclear crowding. These dysplastic nodules can develop into HCC and acquire 
invasive and metastatic ability (Okuda K., 2000). HCC can be graded in well, moderately and 
poorly differentiate HCC. A tumor can be defined as well differentiated when cell 
morphology is similar to normal hepatocytes. Conversely, in poorly differentiated tumors, 
the cells are large and often share common morphological aspects with those of other 
metastatic tumors; they represent in fact the most malignant type of primary HCC.  
Shortening of telomeres is a mechanism involved in chronic liver disease and cirrhosis 
(Urabe Y et al, 1996; Miura N et al, 1997; Rudolph KL et al, 2001; Kitada T et al, 1995); it has 
a role in cancer initiation and contributes to the induction of chromosomal instability (Plentz 
RR et al, 2004 and 2005; Farazi PA et al, 2003). Telomerase reactivation has been associated 
with malignant progression; it is necessary to restore chromosomal stability to a level 
compatible with cancer cell viability (Farazi PA et al, 2003 and 2006).  
The molecular analysis of human HCC has revealed the accumulation of genetic and 
epigenetic modifications that cause significant changes in gene expression and in cellular 
signaling pathways (Aravalli RN et al, 2013). The loss of cell-cycle checkpoints is one of the 
most frequent alterations in HCC; in particular, p53 and Rb proteins are the most affected 
(El-Serag HB. et al. 2007). 
p53 is a critical tumor suppressor; its pathway prevents cell survival and proliferation 
during shortening of telomeres (Wright WE et al, 1992), triggers apoptosis in genotoxic 
stress conditions (Speidel D. et al, 2015), induces cell-cycle arrest in response to oncogene 
activaction (Di Micco R et al, 2006) and promotes genome integrity (El-Serag HB et al, 2007). 
Under normal conditions, p53 cellular levels are low; they are immediately up 
regulated after intracellular and extracellular stress signals. In half of all human tumors 
inactivation of the p53 gene is due to a single point mutation, in others, the expression of 
the p53 protein is not affected but cell signaling pathways involved in cell cycle arrest and 
apoptosis are defective (Stegh AH, 2012). Several studies have shown a critical role of p53 
mutation or inactivation in HCC (Bressac B et al, 1991; Tannapfel A et al, 2001; Jablkowski M 
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et al, 2005; Hsu IC et al, 1993; Lunn RM et al, 1997). Therefore, disruption of p53 checkpoint 
function at the cirrhosis stage could provide a selective advantage allowing proliferation of 
hepatocytes with a critical telomere lenght (El-Serag HB et al, 2007). 
The tumor suppressor retinoblastoma protein (Rb) is a major regulator of cell cycle in 
response to telomere shortening, DNA damage, and oncogene activaction (Wright WE et al, 
1992; Di Micco R et al, 2006). The G1 to S phase transition is regulated by the 
hypophosphorylated Rb gene which sequesters the E2F family of transcription factors 
inhibiting the expression of genes required for entry into S phase. The phosphorylation state 
of Rb is tightly regulated by cyclin-dependent kinases (CDKs) (Goodrich DW. 2006). In human 
HCC, a deregulation of Rb pathway is observed in more than 80% of cases, with a frequent 
repression of the CDK inhibitor p16 due to promoter methylation (Azechi H et al, 2001). 
Besides p53, an impairment of the Rb checkpoint would allow an expansion of hepatocytes 
with altered telomeres during the cirrhosis stage (El-Serag HB et al, 2007). 
Increasing evidence suggests enhanced levels of ROS and RNS (reactive nitrogen 
species) in many types of cancer cells (Kawanishi S et al, 2006; Marra et M al, 2011; Chuma 
et al, 2008). ROS are defined as oxygen-containing chemical species with reactive properties. 
They are produced continuously in cells and derive from metabolic reactions occurring in the 
mitochondria (Handy DE et al, 2012), peroxisomes (Schrader M et al, 2006) and endoplasmic 
reticulum (Malhotra JD et al, 2007). Important free radicals in humans, include superoxide 
(O2
.-), hydroxyl (HO.) and nitric oxide (NO), as well as non-radical molecules such as hydrogen 
peroxide (H2O2) Cells have developed a complete set of antioxidant mechanisms to 
counteract and limit damaging effects of free radical formation. These include the enzymes, 
superoxide dismutase (SOD), glutathione peroxidase (GSH) and catalase. There are further 
antioxidant defences including Vitamin C and E. At moderate levels, ROS can promote cell 
proliferation and differentiation (Boonstra J et al, 2004; Schafer FQ et al, 2001). However, 
the disruption of the redox balance induces high ROS levels that promote cell death and 
cellular damage (Toyokuni S et al, 1995). 
Especially at early stages, cancer cells try to contrast damaging ROS effects, increasing 
ROS scavengers activity that reduce ROS to levels that are compatible with cellular biological 
functions, but still higher than in normal cells (Gorrini C et al, 2013). 
Some of the more frequently activated oncogenic pathways found in human HCC 
include the Wnt/β-catenin, MAPK AKT/mTOR and JAK/STAT (Aravalli et al, 2013). 
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β-catenin is the critical downstream effector in Wnt signaling pathway where it 
mediates a nuclear response after the binding of Wnt proteins to Frizzled receptors at the 
plasma membrane. In unstimulated adult cells, when the Wnt pathway is inactive, β-catenin 
is recruited into a destruction complex with Axin, adenomatous polyposis coli (APC), casein 
kinase 1 (CK1) and glycogen synthase kinase-3β (GSK-3β). CK1 and GSK-3β phosphorylate β-
catenin at specific residues (Amit S et al, 2002) which results in β-catenin recognition by the 
β-transducin repeat-containing protein (βTrCP) for ubiquitination and subsequent 
proteasomal degradation (Monga SP. 2014). 
Binding of Wnt proteins to the Frizzled (Fz) receptor induces the disruption of the 
complex resulting in cytoplasmic accumulation of β-catenin and nuclear translocation. In the 
nucleus, β-catenin binds to the LEF/TCF (lymphoid enhancer factor or T-cell factor), exerting 
its function through the transcriptional regulation of its target genes (Logan CY et al, 2004). 
β-catenin target genes are involved in embryonic and tissue development, cellular 
differentiation, survival, regeneration, self-renewal and in oncogenic transformation of 
several cell types, including hepatocytes (Cadigan KM et al, 1997; Nusse R et al, 2005; Peifer 
M et al, 2000; Willert K et al, 2004.). The aberrant activation of this pathway has been found, 
in about 20-40% of HCC cases, linked to activating β-catenin mutations (De la Coste A et al, 
1998; Zucman-Rossi J et al, 2007). 
MAPK (mitogen-activated protein kinase) cascade transduces signals from tyrosine 
kinase receptors, such as EGFR (Epidermal growth factor receptor), IGFR (Insulin growth 
factor receptor), PDGFR (Platelet derived growth factor receptor), MET, VEGFR (Vascular 
endothelial growth factor receptor), upon the binding to their ligands. In this cascade, active 
Ras (GTP-Ras) causes the sequential activation of Raf, Mek and Erk. The latter transactivates 
numerous growth-related genes such c-Jun, c-Fos, c-Myc. MAPK signaling is involved in cell 
survival, differentiation, adhesion and proliferation (Roberts PJ et al, 2007; Schmidt CM et al, 
1997). Moreover, it is often found to be deregulated in various types of human tumors, 
including HCC (Huang P et al, 2010; Wagner EF et al, 2009). 
The PI3K/Akt/mTOR pathway also plays an important role in cell growth, survival 
regulation, metabolism, and inhibition of apoptosis (Kudo M. 2012). It acts through 
phosphatidylinositol-3-kinase (PI3K) and generation of phosphatidyl inositol 3,4,5-
triphosphate (PIP3), which binds to and activates the serine/threonine kinase Thymoma viral 
protooncogene (Akt/PkB) (Woodgett JR. 2005). Activation of Akt signaling and impaired 
expression of phosphatase and tensin homolog (PTEN) (a negative regulator of Akt) have 
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been reported in 40%–60% of human HCC (Hu TH et al, 2003). The serine/threonine kinase 
mTOR (mammalian target of rapamycin) is an important mediator in the PI3K/Akt pathway, 
that regulates protein synthesis mediating cell growth (Engelman JA et al, 2009). 
Signal transducers and activators of transcription (STATs), which consist of a family of 
transcription factors, are activated by a large number of cytokines, hormones, and growth 
factors (Harrison DA. 2012) through tyrosine phosphorylation by Janus kinases (JAKs). 
Activated STATs stimulate the transcription of suppressors of cytokine signaling (SOCS) genes 
and their proteins that act to negatively regulate receptor complexes by inactivating JAKs or 
blocking recruitment sites for STATs. The JAK/STAT pathway activates cell proliferation, 
migration, differentiation, and apoptosis (Yoshikawa H et al, 2001). The activation of 
JAK/STAT pathway as consequence of a deregulation of SOCS has been reported in HCC 
(Calvisi DF. et al. 2006) 
 
1.4. Clinical aspects 
The knowledge of the main risk factors, and the mechanisms through which these act, 
could help to reduce the incidence of HCC, through appropriate prevention that aims to limit 
viral transmission and alcoholism. The spread of HBV infection can be effectively reduced by 
vaccination. In Italy a mandatory vaccination policy was introduce in 1991 for all new borns 
and 12 year old adolescents, and a screening for women in the third quarter of pregnancy 
(Zanetti AR et al, 2008). To date, unfortunately, there is no vaccine against HCV and 
prevention of infection should focus on proper health care conditions. Moreover, public 
awareness regarding the risks of excessive alcohol consumption might contribute to the 
reduction of HCC risk (Bruix J et al, 2004). 
If effective primary prevention is not possible, other approaches aimed at preventing 
the spread of these viruses are necessary in order to remove risk factors and their ability to 
induce chronic liver damage and cirrhosis. The effect of antiviral therapy in patients with 
chronic hepatitis B or C on the prevention of the development of HCC is controversial. 
Therefore, the only strategy is the early detection that can be achieved with a 
surveillance program (Bruix J et al, 2004). A liver ultrasonography every 6 months is 
recommended only for patients with cirrhosis of any etiology or for those without cirrhosis 
but with chronic HBV infection (Bruix J et al, 2011). It is well tolerated and widely available, 
and capable of achieving sensitivity of 60–80% and specificity beyond 90%. (Singal A et al, 
2009). The serological test of α-fetoprotein (AFP) is no longer recommended for effective 
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surveillance because of its low diagnostic sensitivity and specificity (Singal A et al, 2009; Lok 
AS et al, 2010). 
Moreover, the histological grade and the staging of the tumor are important 
prognostic factors in the management of patients, in assessment of prognosis and in 
treatment assignment.  
The histologic grading of HCC is usually evaluated by the Edmondson and Steiner (ES) 
grading system, which was first described in 1954 (Edmondson HA et al, 1954). The 
diagnostic criteria used by the authors to determine the degree of cell differentiation are the 
quality of the cytoplasm (quantity, granularity and acidophilia), the nuclear aspect (size and 
degree of hyperchromatism) and the nuclear/cytoplasmic ratio. They also included the 
cohesive quality, the function and the architecture of tumor cells. Using these criteria the 
authors classified tumors into four grades.  
Grade I belong to the best differentiated tumors. Its diagnosis is possible only after the 
demonstration of more aggressive growths in other parts of the carcinoma with grade II.  
Cells in grade II are similar to normal hepatic cells with hyperchromatic and larger 
nuclei than normal with an acidophilic, abundant cytoplasm. Acini are frequent and their 
lumina of various sizes are often filled with bile or protein precipitate.  
In grade III nuclei of tumor cells are progressively larger and more hyperchromatic but 
with less cytoplasm; this is acidophilic and with segregation of granular material toward the 
cell border. Some breakup or distortion of the usual trabecular pattern is present. Tumor 
giant cells are numerous. 
Grade IV is characterised by the presence of intensely hyperchromatic nuclei that 
occupy a greater portion of the cell with a scanty and less granular cytoplasm. Another 
characteristic of these tumors is the loss of trabecular pattern and the lack of cohesiveness 
of the cells that would predispose to early and widespread metastases. 
Importantly, grading heterogeneity inside a tumor is frequently observed, making 
difficult the classification of the tumor (Pawlik TM et al, 2007). Accordingly, and compared to 
other carcinomas, HCCs are usually classified in well-, moderately and poorly differentiated 
(Paradis V. 2013). 
The Barcelona Clinic Liver Cancer (BCLC) staging classification was first published in 
1999 (Llovet JM et al, 1999) and has been refined and further developed in 2003 (Llovet JM 
et al, 2003). This system is widely accepted to stratify individual tumors according to the 
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different available treatments. In agreement to this staging system, patients can be classified 
into five groups: very early, early, intermediate, advanced and end-stage. 
The very early stage includes patients with a well compensated cirrhosis, single and 
well differentiated HCC, less than 2 cm in size. The diagnosis of tumor is possible only after 
surgery and these patients can benefit of curative treatments. 
Asymptomatic patients with single HCC smaller than 5 cm in diameter or three nodules 
equal or less than 3 cm compose the early stage (Mazzaferro V et al, 1996). These patients 
with preserved liver function are candidate to curative treatments. 
The intermediate stage is formed by patients with large, multifocal HCCs, who are 
asymptomatic and without an invasive pattern, defined as macrovascular invasion or 
extrahepatic spread. In these patients the transarterial chemoembolization (TACE) is 
considered the elective treatment. 
The advanced stage is characterized by patients with mild cancer-related symptoms 
and an invasive pattern. Until very recently, there was no effective treatment and patients 
were therefore candidates for therapeutic trials.  
The end-stage is characterized by an extensive tumor involvement and an impaired 
physical status. It also includes patients with severe impairment of liver function and 
unsuitable for transplantation. The expected survival is shorter than 3–6 months and these 
patients should be treated only with palliative therapies. 
In according with BCLC system, patients can therefore be assigned to different 
therapeutic strategies. Patients diagnosed at an early stage can undergo curative treatments 
such as surgical resection, transplantation or percutaneous ablation; they offer a high rate of 
complete responses and, thus, potential for cure. Treatment options for HCC include also 
palliative care, which is not aimed to cure, but in some cases can obtain good response rate 
and even improve survival (Llovet JM et al, 2003). Unfortunately, only 30%-40% of patients 
benefit of these treatments in western countries and hence the vast majority receive 
palliative therapy (Bruix J et al, 2002). 
Surgical resection is reserved to patients with very early and early stage HCC and 
without portal hypertension (Bruix J et al, 1996). This patients are the best candidates for 
the resection of a hepatic segment, with survival rates exceeding 60%-70% at 5 years; the 
major pitfall is the high rate of tumor recurrence being more than 50% at 3 years during 
follow-up (Llovet JM et al, 2003). 
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Liver transplantation is the treatment option for patients with early HCC in 
decompensated cirrhosis; the 5-year survival rate is over 70% and the risk of tumor 
recurrence is less than with surgery (Llovet JM et al, 2003). The main obstacle of this 
treatment is the paucity of donor livers; it increases the waiting time for transplantation and 
leads to patients drop out from the waiting list as a consequence of HCC progression. The 
monthly drop-out rate is around 4% (Sarasin FP et al, 2001; Llovet JM et al, 2005) 
Percutaneous ablation is the treatment of choice for early, unresectable HCC (Livraghi 
T et al, 1995; Lencioni R et al, 1997; Rossi S et al, 1996; Buscarini L et al, 2001; Okada S et al, 
1999). Destruction of tumor tissue can be obtained by direct injection of chemical 
substances (ethanol, acetic acid, boiling saline) or by physical modification of the cancerous 
tissue temperature (radiofrequency, microwave, laser, cryotherapy) (Okada S et al, 1999). 
This treatment modality has the advantage of a very short hospitalization, low cost and rare 
complications (Livraghi T et al, 1995). Efficacy of percutaneous ablation, defined as absence 
of contrast uptake on computerized tomography one month after the procedure (Bruix J et 
al, 2001), greatly depends on tumor size. It decreases from 90-100% in HCCs less than 2 cm, 
with a survival rate a 5-years of 71%, to 70% in HCCs sized 2–3 cm and 50% in HCCs sized 3–5 
cm (Okada S et al, 1999; Mazzanti R et al, 2004a,b). 
Palliative treatments can be proposed to patients in intermediate and advanced tumor 
stage that do not benefit from curative interventions. They include transarterial 
chemoembolization (TACE), transarterial embolization alone (TAE), intra-artery 
chemotherapy (IACT) and radiation therapy (Mazzanti R et al, 2007). Systemic chemotherapy 
with several kinds of drugs as well as hormonal therapy have been shown to be ineffective in 
the treatment of HCC, toxic, and without survival benefits (Bruix J and Sherman M. 2005). 
Among palliative treatments only TACE with cisplatin or doxorubicin has been proven to 
improve survival (Llovet JM and Bruix J, 2003); it is indicated in patients with intermediate 
stage HCC or early tumors in which curative treatments are unfeasible (Mazzanti R et al, 
2008). Chemoembolization combines selective injection of chemotherapeutic drugs into the 
hepatic artery with obstruction of the vessels feeding the tumor. Despite the large use of 
TACE in treatment of unresectable HCCs, an universally standard protocol is currently not 
available. Patients with portal thrombosis or advanced disease in which TACE treatment is 
not recommended could ameliorate their survival by IACT (Mazzanti R et al, 2008); a pilot 
study has shown a benefical effect of 5-fluorouracil (5-FU) infusion on response rate and 
survival (Mazzanti R et al, 2004a). 
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The advent of targeted therapies and the approval of the systemic treatment of 
advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. 
Currently, only sorafenib is approved for HCC treatment; however, it improves survival by 
only a couple of months. Consequently, HCC remains one of the few cancer types with an 
increasing cancer-related mortality. Although no definite breakthrough in treatment is 
currently in sight, new therapeutic targets have recently come to the spotlight. One of these 
targets is the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), encoded by 
the MET gene, known to promote tumor growth and metastasis in many human organs. 
 
1.5. Animal model of hepatocarcinogenesis 
Due to the multistage nature of HCC, the molecular pathogenesis of this cancer cannot 
be properly understood without more information on the molecular alterations 
characterizing its early development. Unfortunately, the study of the early steps of HCC 
development in humans is complicated due to the late stage in which the tumor is diagnosed 
and to the heterogeneity inside a tumor that makes difficult a clinical classification. 
Therefore, animals model that enable dissection of the several steps of 
hepatocarcinogenesis are required.  
In my thesis we used two different rodent models of hepatocarcinogenesis to 
investigate which alterations found in HCC could take place at early stages of the process, 
suggesting therefore their possible critical role. 
The first model employed was the rat Resistant-Hepatocyte (R-H). The R-H or Solt-
Farber rat model (Solt DB et al, 1977) allows the identification of phenotypically distinct 
lesions along the various steps of liver carcinogenesis in the rat (early nodules, adenomas, 
early HCCs, and advanced HCCs). 
This experimental model constists of a classical initiation-promotion procedure: 
initiation of hepatocytes is determined by a single necrogenic dose of diethylnitrosamine 
(DENA); promotion is achieved by 2 weeks of dietary exposure to 2-acetylaminofluorene (2-
AAF), that selectively inhibits the proliferation of normal hepatocytes and 2/3 partial 
hepatectomy (PH) as a growth stimulus for DENA-initiated hepatocytes. 
Initiated cells, unlike normal hepatocytes, are indeed capable to clonally expand and 
rapidly give rise to early preneoplastic lesions identifiable by their positivity to the placental 
form of the enzyme glutathione-S-transferase (GSTP). During the carcinogenic process, the 
vast majority of the preneoplastic lesions re-differentiate througha process named 
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remodeling (Enomoto K et al, 1982) with a gradual loss of the GSTP and other preneoplastic 
markers (Perra A et al, 2009). Only persistent nodules progress, to adenomas and early HCCs 
(eHCCs) clearly visible at about 10 months after DENA initiation. Fourteen months after 
initiation, all rats present advanced HCCs (aHCCs). 
Previous studies allowed to distinguish within GSTP+ preneoplastic lesions, , a 
subpopulation of persistent nodules that express the intermediate filament protein 
cytokeratin 19 (KRT-19) (Andersen JB et al, 2010).  
KRT-19 is expressed in normal adult liver only in epithelial cells of the bile ducts, but 
not in hepatocytes. Its abnormal expression is found in several pathological conditions 
including remodeling of the parenchyma in livers with chronic hepatitis or cirrhosis, 
capillarization of hepatic sinusoids and ductular oval cell proliferation (Su Q et al, 2003). 
A comparative analysis of the gene expression profiles of early preneoplastic lesions 
and of early and advanced HCCs, has revealed a common signature, thus demonstrating 
their ability to progress to HCC, giving rise to almost all HCCs generated in the Resistant 
hepatocyte model (Andersen JB et al, 2010). Furthermore, the gene expression signature 
associated with the rat lesions positive for the stem/progenitor cell marker KRT-19 predicts 
the clinical outcome of human HCC, giving a translational value to this model (Petrelli A et al, 
2014). 
In the second animal model, female C3H/HeNCrl mice were treated chronically with 
repeated doses of the CAR (Constitutive androstane receptor) ligand TCPOBOP (1,4-bis[2-
(3,5-dichloropyridyloxy)]benzene), with or withouth a single administration of DENA. 
TCPOBOP is the most potent nuclear receptor CAR agonist, that similar to 
phenobarbital, induces liver hyperplasia and hypertrophy in mice (Dragani TA et al, 1985; 
Manenti G et al, 1987) by accelerating the entry of hepatocytes into the S phase of cell cycle 
(Ledda-Columbano et al, 2000). Moreover, TCPOBOP is both a nongenotoxic carcinogen on 
its own and a potent tumor promoter when combined with genotoxic agents (Diwan BA et 
al, 1992; Columbano A et al, 2003; Ledda-Columbano GM et al, 2000; Locker J et al, 2003). In 
our study TCPOBOP induces the development of HCCs in mice treated with or without DENA 
after 28 and 42 weeks, respectively. 
 
2. Hydroxy acid oxidases 
L-2 Hydroxy acid oxidases are flavin mononucleotide (FMN)-dependent peroxisomal 
enzymes. Although their role is still unknown, these enzymes are members of the 
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flavoenzyme family capable of oxidizing several 2-hydroxy acids, ranging from glycolate to 
long chain 2-hydroxy fatty acids such as 2-hydroxypalmitate (Angermüller S et al, 1989; Fry 
DW et al, 1979; Schwam H et al, 1979), to 2-keto acids. This reaction results in hydrogen 
peroxide (H2O2) formation at the expense of molecular oxygen (Jones JM et al, 2000) (Fig. 1).  
 
 
Fig. 1. Schematic representation of the catalytic reaction of hydroxy acid oxidases 
 
 
Other enzymes belonging to this family have been identified in different organisms: 
flavocytochrome b2 or L-lactate dehydrogenase (FCB2) from yeast (Lederer F. 1991), lactate 
monooxygenase (LMO) from Mycobacterium (Ghisla S et al, 1991), lactate oxidase (LOX) 
from Aerococcus Viridans (Maeda-Yorita, K et al, 1995), mandelate dehydrogenase (MDH) 
from Pseudomonas putida (Lehoux IE et al, 1999) and glycolate oxidase from plants (Volokita 
M et al, 1987).  
In mammals, 2-hydroxy acid activity was first described in rat, both in kidney and liver 
(Blanchard M et al, 1944; 1945; 1946); it was also reported in mouse (Duley J et al, 1974) and 
hog renal cortex (Robinson JC et al, 1962). In both prokaryotes and eukaryotes, all family 
members share a highly conserved nucleotide and amino acid sequences (Barawkar DA et al, 
2012). 
Only at the beginning of the 21st century, Jones and collaborators identified for the 
first time three human 2-hydroxy acid oxidases named HAO1, HAO2, and HAO3 (also known 
as HaoX1, HaoX2 and HaoX3), homologs of plant glycolate oxidase, which encode 
peroxisomal proteins with 2-hydroxy acid oxidase activity (Jones JM et al, 2000). In 
particular, the human HAO1 cDNA is 1743 bp in length and codes a protein of 370 amino 
acids with a predicted molecular weight of 41 kDa. The HAO2 cDNA is 1417 bp long encoding 
a protein of 351 amino acids with an estimated molecular weight of 39 kDa. The HAO3 cDNA 
sequence is 1821 bp which encodes a predicted protein of 353 amino acids and a molecular 
mass of 39 kDa. HAO2 and HAO3 share 70.4% sequence identity and only about 45% with 
HAO1. As described by Jones and colleagues, all three gene products show substrate 
preference and distinct tissue expression patterns. HAO1 is expressed at high levels in liver 
and pancreas and to a much lesser extent in kidney and placenta, displaying the highest 
activity with glycolate but also toward glyoxylate, 2-hydroxyoctanoate, and 2-
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hydroxypalmitate. High expression levels of HAO2 were detected both in liver and kidney 
with small amounts also in thymus. It is preferentially active against long chain 2-hydroxy 
acids, in particular 2-hydroxyoctanoate or 2-hydroxypalmitate. HAO3 is found to be 
expressed primarily in pancreas with 2-hydroxyoctanoate as substrate. 
Very few data are available in the literature about human 2-hydroxy acid oxidases; to 
date, their functional role remains to be identified. 
Some studies focused on Hao2 have been conducted in rat models of genetic 
hypertension, in order to investigate genetic determinants of blood pressure regulation. In 
fact, Hao2 has been identified as a candidate gene for the systolic blood pressure 
quantitative trait loci (QLT) in rats (Lee SJ et al, 2003); another genome-wide linkage study 
seemed to confirm the potential relation between Hao2 and hypertension in humans (Rico-
Sanz J et al, 2004). To establish the involvement of Hao2 in blood pressure regulation, 
several authors, availing themselves of the rat Hao2 crystal structure (Cunane LM et al, 
2005) developed potent and selective rat Hao2 inhibitors (Barawkar DA et al, 2011; 2012) 
that seem to inhibit Hao2 leading to a reduction of blood pressure in the rat hypertension 
models analysed.  
Another study (Ma Q et al, 2007) showed the possible role of Hao2 in the treatment of 
patients with sickle cell anemia in response to hydroxyurea, a drug that increases 
concentration of fetal hemoglobin (HbF) inhibiting the polymeration of sickle hemoglobin 
(HbS). This study suggests that single nucleotide polymorphisms (SNPs) of several genes, 
including Hao2, are associated with the HbF response to treatment with hydroxyurea. 
In their work on the identification of the three human hydroxy acid oxidases (Jones JM 
et al, 2000), Jones and coworkers hypothesized their possible contribution in α-oxidation of 
fatty acids. Their oxidative metabolism can proceed by distinct pathways, including α-, β- 
and ω-oxidation (Wanders RJ et al, 2011). 
The discovery of fatty acid α-oxidation is closely related to the finding of high amounts 
of phytanic acid in kidney, liver and brain of patients affected with Refsum disease, a rare 
genetic disease characterized by retinitis pigmentosa polyneuropathy, deafness, ataxia, 
ichthyosis and cardiac manifestations. 
α-oxidation in humans is a process in which 3-methyl branched fatty acids, such as 
phytanic acid, are shortened to 2-methyl branched fatty acids, which can then be further 
degraded by peroxisomal and mitochondrial β-oxidation (Fig. 2). Despite several studies 
some of the individual enzymatic steps remain to be identified. Research focused on the 
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definition of this pathway reveals that this mechanism is predominantly, if not exclusively, 
peroxisomal (Jansen GA et al, 2006). 
 
 
Fig. 2. The phytanic acid alpha-oxidation pathway. Adapted from Foulon V et al, 2005. 
 
 
The first step in α-oxidation involved the activation of phytanic acid to phytanoil CoA 
by acyl-CoA synthetase (Watkins PA et al, 1994), which can occur in mitochondria, 
endoplasmic reticulum and peroxisomes (Wanders RJ et a., 2011). In the second step, 
phytanoyl-CoA 2-hydroxylase (PAHX), a PTS2 (peroxisomal targeting signal) containing 
peroxisomal matrix protein, catalyzes the hydroxylation of phytanoil CoA to form 2-
hydroxyphytanoyl-CoA (Mihalik SJ et al, 1995; Jansen GA et al, 1999a) which is subsequently 
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decarboxylated to pristanal and formyl-CoA by 2-hydroxyphytanoyl-CoA (Foulon V et al, 
1999; Jansen GA et al, 1999b). In the last step, pristanal is converted into pristanic acid in a 
reaction catalized by aldehyde dehydrogenase (Jansen GA et al, 2001) which is then further 
degraded by peroxisomal β-oxidation. 
Alternatively to this model, some reports indicate a second pathway in which fatty acid 
α-oxidation may involve the formation of 2-ketophytanic acids intermediate from 2-
hydroxyphytanic acids, both in rat and human liver (Fig. 3) (Wanders RJ et al, 1995; Vamecq, 
J. et al, 1988; Verhoeven, NM et al, 1997; Wanders RJ et al, 1994). 
 
 
Fig. 3. Formation of pristanic acid from 2-hydroxyphytanic acid. Adapted from Verhoeven NM et al, 
1997. 
 
These studies suggest that, at least in rat liver, this conversion is catalyzed by an 
enzyme localized in peroxisomes which uses molecular oxygen as second substrate. The 
subsequent finding that the formation of 2-ketophytanic acid is strongly reduced if 
molecular oxygen is substituted by nitrogen, and it is also associated with H2O2 formation, 
further supports the involvement of an oxidase in the reaction. 
Unfortunately, this mechanism is still under debate and to date the role of hydroxy 
acid oxidases still needs to be clarified. 
As previously described, hydroxy acids oxidase are peroxisomal enzymes and produce 
H2O2 as part of their normal catalytic cycle. In 2003, Recalcati and colleagues showed in rat a 
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down-regulation of Hao1 in response to oxidative stress, thus providing that a decrease of 
this ROS producing enzyme may prevent excessive H2O2 formation in liver peroxisomes 
(Recalcalti S et al, 2003). 
Peroxisomes are subcellular organelles bounded by a single membrane, which are 
present in the majority of eukaryotic cells. They were isolated and characterized by de Duve 
that defined them as a cell organelle which contains at least one H2O2-producing oxidase 
together with catalase, a H2O2-degrading enzyme (de Duve C. 1965). Mammalian 
peroxisomes play a pivotal role in metabolic pathways, including fatty acids α- and β-
oxidation, ether-phospholipid biosynthesis, glyoxylate metabolism, amino acid catabolism, 
polyamine oxidation, and the oxidative part of the pentose phosphate pathway (Wanders RJ 
et al, 2006). Many of the enzymes participating in these pathways produce ROS and RNS as 
byproducts of their catalytic reactions (Antonenkov VD et al, 2010). It has been estimated 
that peroxisomes contribute to 35% of the H2O2 production in rat liver (de Duve C et al, 
1966), inducing oxidative stress; this is also confirmed by the long-term administration of 
peroxisome proliferators in rodent liver cells (Kasai H et al, 1989). 
Numerous observations indicate also that peroxisomes contain various ROS- 
metabolizing enzymes protecting cells from oxidative stress and accounting for 20% of the 
oxigen consumption in rat liver (Boveris A et al, 1972). Indeed, an abnormal functioning of 
peroxisomes causes increase apoptosis in the development of mouse cerebellum (Krysko O 
et al, 2007); in humans, an inherited deficiency of catalase, the most abundant peroxisomal 
ROS-metabolizing enzyme, induces an increased risk of developing age-related diseases such 
as diabetes, atherosclerosis, and cancer (Góth L et al, 2000). 
These findings collectively suggest the idea that peroxisomal metabolism and cellular 
oxidative stress are closely interconnected (Fransen M et al, 2012; Bonekamp NA et al, 2009; 
Schrader M et al, 2006). 
Overall, very few data are present in literature about hydroxy acid oxidases and their 
role is still unclear. 
The role of Hao2 in cancer is still unknown. A study of gene expression profiles for 
human intrahepatic cholangiocarcinoma showed among down-regulated genes also Hao2 
(Wang AG et al, 2006), although no hypothesis about its role have been proposed by the 
authors.  
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AIM OF THE WORK 
 
 
Previous microarray analysis done in our laboratory has shown that Hao2 was one of 
the most down-regulated genes in advanced HCCs developed with the R-H model of 
hepatocarcinogenesis. Since its role is still unclear and no studies are reported in the 
literature about Hao2 and cancer, the aim of my PhD thesis was to shed light on the possible 
role of Hao2 in HCC development, in two different rodent models and in two distinct cohorts 
of human patients. Furthermore, using a multistage model of rat hepatocarcinogenesis, I 
also wished to determine whether alterations of the expression of Hao2 could take place at 
early stages of the tumorigenic process. 
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MATERIALS AND METHODS 
 
 
1. Animals and Treatments 
Male Fischer 344 (F-344) rats and female C3H/HeNCrl mice were purchased from 
Charles River Laboratories (Milano, Italy). Before starting experimental procedures, animals 
were housed at constant room temperature (25°C) and 12 hours light/dark cycles and fed 
with rodent standard diet (Mucedola, Milano, Italy) and ad libitum access to water. Guide for 
Care and Use of Laboratory Animals were followed during the investigation. All animal 
procedures were approved by the Ethical Commission of the University of Cagliari and the 
Italian Ministry of Health. 
Rat Model of hepatocarcinogenesis: Rats were subjected to the Resistant-Hepatocyte 
(R-H) model (Solt DB et al, 1977, Fig. 4), which consists of a single intraperitoneal injection of 
150 mg/kg body weight of diethylnitrosamine (DENA, Sigma Aldrich, Milano, Italy) dissolved 
in saline. Following a 2-week recovery period, rats were fed a diet containing 0.02% 2-
acetylaminofluorene (2-AAF, Sigma Aldrich, Milano, Italy) for two weeks, that induces a 
cytostatic effect on normal hepatocytes. To trigger the rapid growth of DENA-initiated 
hepatocytes which are resistant to the mitoinhibitory effect of 2-AAF, one week after the 
exposure to 2-AAF, rats underwent a standard two-thirds partial hepatectomy (PH) (Higgins 
GM et al, 1931). Rats were then maintained on basal diet all throughout the experiment and 
sacrificed 10 weeks and 14 months after DENA administration. 
 
 
Fig. 4. The Solt-Farber Resistant-Hepatocyte rat model. 
 
 
To assess the expression levels of Hao2 during liver regeneration, rats were subjected 
to a standard 2/3 PH (Higgins GM et al, 1931), and sacrificed after 24, 48 and 168 hours. 
Livers collected at the time of the surgery were used as controls. 
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Mouse model of hepatocarcinogenesis: Mice were randomized into two experimental 
protocols. The first group (Fig. 5A) was injected intraperitoneally with DENA, dissolved in 
saline, at a dose of 90 mg/kg body weight. After one week of recovery period, mice were 
treated once a week with the Constitutive Androstane Receptor (CAR) ligand TCPOBOP 
(3mg/kg body weight) dissolved in dimethyl sulfoxide (DMSO) and given intragastrically in a 
corn-oil solutionl. Matched-aged mice treated only with TCPOBOP were used as controls.  
The second group (Fig. 5B) was given weekly intragastric doses of TCPOBOP (3 mg/kg 
body weight), in the absence of DENA administration. Matched-aged mice treated with corn 
oil were used as control. Mice were sacrificed after 42 weeks of treatment, a time point 
when HCCs were observed. Mice treated weekly with corn oil were used as controls. 
 
 
Fig. 5. Schematic representation of experimental mouse models. HCC was generated by A) a 
single injection of DENA followed by treatment with the CAR ligand TCPOBOP 
(once/week/28 weeks), B) repeated doses of the non-genotoxic agent TCPOBOP 
(once/week/42 weeks), in the absence of DENA pre-treatment.  
 
 
In both rat and mouse protocols, immediately after the sacrifice, livers were divided 
into several sections which were stored according to three different methods. Sections were 
fixed in 10% buffer formalin, embedded in paraffin and stored at room temperature for 
25 
 
 
immunohistochemistry staining. Other sections of the liver were snap-frozen in isopentane 
(2-Methylbutane) and liquid nitrogen, and immediately kept at -80°C for criosectioning. The 
remaining liver was snap-frozen in liquid nitrogen and stored at -80°C for DNA, RNA and 
protein extraction. 
 
2. Immunohistochemistry 
Isopentane-frozen rat liver sections were serially sliced at 6 µm thickness using a Leica 
CM 1950 cryostat, mounted directly on super frost slides (Fisher Scientific, Pittsburgh PA), 
and air dried for 5 minutes before immunohistochemical staining. 
 
2.1. Hematoxilin and eosin staining 
Liver sections were fixed in acetone at -20°C for 5 minutes and stained for 3 minutes 
with Mayer’s haematoxylin and 1% aqueous eosin for 20 seconds. Sections were then 
dehydrated through ascending alcohol series, cleared with xylene, air-dried and then 
mounted using synthetic mounting and coverslipped. 
 
2.2. Glutathione S-transferase staining 
Frozen liver section were fixed in 10% buffer formalin for 6 hours. After several washes 
in water and in phosphate buffered saline (PBS), endogenous peroxidase activity was 
blocked by 0,3% hydrogen peroxide (Sigma-Aldrich, Milano, Italy) in distilled water for 10 
minutes. Unspecific binding sites were then removed by incubating section for 30 minutes in 
1:10 normal goat serum in PBS. Slides were then incubated overnight at 4°C with 1:1000 
anti-GSTP antibody (MBL, 311, Nagoya, Japan) and with anti-rabbit Horseradish Peroxidase 
(HRP) conjugated antibody (Sigma Aldrich, Milano, Italy) at a dilution of 1:300 for 30 minutes 
at room temperature. Positive reaction was visualized by 3, 3′-diaminobenzidine (DAB, Sigma 
Aldrich, Milano, Italy) for 6 minutes at room temperature. Sections were counterstained 
with Harris hematoxylin, dehydrated through graded alcohols, cleared and mounted in 
synthetic mounting media. 
 
2.3. Cytokeratin-19 staining 
Frozen liver sections were fixed in cold acetone for 20 minutes. Block of endogenous 
peroxidases and aspecific sites were performed as described previously for GSTP staining. 
Slides were then incubated with primary mouse polyclonal anti-Krt-19 antibody (Novocastra, 
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NCL-CK19, Leica Biosystems, Milano, Italy) at a dilution of 1:100 overnight a 4°C and then 
with 1:200 anti-mouse Horseradish Peroxidase (HRP, Sigma-Aldrich, Milano, Italy) 
conjugated antibody at room temperature for 30 minutes. Staining was developed with 3,3′-
diaminobenzidine (DAB) for 6 min at room temperature, and then tissue sections were 
counterstained with Harris hematoxylin dehydrated in graded alcohols, and mounted in 
synthetic mounting media. 
 
3. Laser capture microdissection 
Sixteen-μm-thick serial frozen sections were cut and attached to 2-μm RNase free PEN-
membrane slides (Leica, Wetzlar, Germany). Immediately before micro-dissection, frozen 
sections were stained by a 2.45 minutes H&E procedure. Briefly, sections were rapidly 
hydrated (30 seconds in Ethanol 100 and 95%), stained in Mayer’s hematoxilin for 90 
seconds, washed in water for 20 seconds, stained in 0.5% alcoholic Eosin for 10 seconds and 
dehydrated by Ethanol 100% for 30 seconds. Then, sections were microdissected by Leica 
LMD6000 (Leica Microsystems Inc., Buffalo Grove, IL); the whole procedure was performed 
within 20 minutes to prevent RNA degradation. Microdissected lesions were collected into 
caps of 0.5 ml microcentrifuge tubes filled with 100 μl of Extraction Buffer (XB) and 
incubated for 30 minutes at 42°C. To collect tissue extracts into the microcentrifuge tubes, 
samples were centrifugated at 800 x g for two minutes and then frozen at -80°C until 
extraction with PicoPure RNA isolation kit (Arcturus, Life Technologies, Monza, Italy). 
 
4. RNA extraction 
 
4.1. RNA isolation using PicoPure RNA isolation kit  
Total RNA was isolated from rat micro-dissected lesions (controls, preneoplastic 
lesions and HCCs) with PicoPure RNA isolation kit according to manifacturer’s instructions. 
Briefly, after pre-condition of the RNA Purification Column with Conditioning Buffer (CB), 
100 μl of 70% ethanol was added to the tissue extract, transferred to RNA purification 
column and centrifuged at 100 x g for 2 minutes for RNA binding, followed by a quick spin at 
16000 x g for 30 seconds to remove flowthrough. RNA Purification Column was then washed 
three times by Washing Buffer 1 and 2 and then transferred to a new 0.5 ml microcentrifuge 
tube provided by the kit. Sixteen μl of DNase/RNase free distilled water (Gibco, Life 
technologies, Monza, Italy) was added; the tube assembly was left to incubate at room 
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temperature for 1 minute and centrifuged at 1000 x g for 1 minute to distribute elution 
buffer in the column, followed by spinning at 16000 x g for 1 minute to elute RNA. The 
eluted RNA was then stored at -80°C. 
 
4.2. RNA isolation using TRIzol® Reagent  
Total RNA from frozen mouse, human tissue and human HCC cell lines was extracted 
using TRIzol® Reagent (Invitrogen, Life Technologies, Monza, Italy), according to 
manifacturer’s instructions. 
Briefly, 1 ml of TRIzol was added to 50-100 mg of hepatic tissue. Samples were 
homogenized with a Polytron homogenizer and incubated 5 minutes at room temperature to 
permit the complete dissociation of nucleoprotein complex. Then, 0.2 ml chloroform/ml of 
TRIzol, were added, shaked by hand for 15 seconds and incubated for 3 minutes at room 
temperature. After centrifugation (15 minutes at 12000 x g at 4°C) the mixture was 
separated into three phases: a lower red phenol-chloroform phase containing proteins, a 
white interphase containing DNA, and a colorless upper aqueous phase containing RNA. 
Aqueous phase was transferred into a new tube and RNA was precipitated by addition of 
500 ml 100% isopropanol followed by 10 minutes incubation at room temperature and 
centrifugation at +4°C at 12000 x g for 10 minutes. The resulting RNA pellet was washed in 
75% ethanol and dissolved DNase/RNase free distilled water in at heat block set at 60°C for 
10 minutes.  
 
5. Quantitative and qualitative analysis of nucleic acids 
Total RNA concentrations and purity ratios (260/280 and 260/230) were measured 
using NanoDrop 1000 Spectrophotometer (Thermo Scientific, France). RNA integrity was 
assessed by Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) by 
evaluating the RNA Integrity Number (RIN). All procedures were performed according to 
manufacturer’s protocol. Only RNA samples with a RIN equal to or higher than 7 were 
further used in the study. 
 
6. RT-PCR (Reverse Transcription Polymerase Chain Reaction) 
To investigate by quantitative real time-PCR (qRT-PCR) mRNA expression levels of 
Hao2, total RNA was retro-transcribed to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystem, Life Technologies, Italy). 
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Different amounts of total RNA were diluted in 10 μl of DNase/RNase free distilled 
water. The 20 μl reaction mixture contained: 2 μl of RT buffer (10X), 2 μl of Random Primers 
(10X), 0.8 μl of dNTP mix (100 mM), 1 μl of MultiScribe Reverse Transcriptase, 1 μl of RNase 
Inhibitor and 3.2 μl of DNase/RNase free distilled water and 10 μl of the appropriate total 
RNA at the desired concentration. Thermo cycle condition was: 25° C for 10 minutes, 37° C 
for 120 minutes and 85° C for 5 minutes, followed by a 4° C hold. Samples were then stored 
at -20° C until next use.  
 
7. Quantitative Real Time PCR  
Retro-transcribed cDNAs were used for gene expression analysis performed by qRT-
PCR. Reaction mixtures were prepared to a final volume of 10 μl containing: 4 μl of cDNA 
template (2.5 ng/μl), 5 μl of 2X TaqMan Gene Expression Master Mix (Applied Biosystem, 
Life Technologies, Italy), 0.5 μl of 20X TaqMan assay (Applied Biosystem, Life Technologies, 
Italy) and 0.5 μl of RNase free water. 
The following TaqMan probes were used for Hao2 gene expression: Rn00583454_m1 
for rat, Mm00469507_m1 for mouse and Hs00213002_m1 for human. 
Reactions were performed in a ABI PRISM 7300HT thermocycler (Applied Biosystem, 
Life Technologies, Italy); the cycle conditions were set as follows: 50° C for 2 minutes and 95° 
C for 10 minutes, followed by 40 cycles at 95° C for 15 seconds and at 60° C for 1 minute. 
Each sample was analysed in triplicate; the housekeeping genes rat and mouse GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) and human β-actin were used for 
normalization. To determine the relative expression levels of Hao2, the 2−ΔΔCT method was 
used. The threshold cycle (Ct) value of the target gene was normalized to that of the 
endogenous reference and compared with a calibrator.  
 
8. Protein isolation  
Rat liver samples were homogenized in RIPA Buffer (1X PBS, 1% Igepal CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitor cocktail 
(Sigma-Aldrich, Milano, Italy) with a Polytron homogenizer and centrifuged two times at 
12000 rpm for 15 minutes at 4 °C. The supernatant was collected in a new tube and stored at 
-80 °C. 
Proteins from human HCC cell lines were directly extracted using Laemmli buffer (Tris-
HCl 0.5M, pH 6.8, SDS 10%), pre-warmed at 95°C, which was dispensed on cells on a culture 
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dish (after removal of media and washing with PBS). Cells were then gently scraped from the 
culture dish and transferred into a 1.5 ml tube. Samples were incubated in an heating block 
at 95°C for 3 minutes and then stored at -80°C. 
Protein concentrations of both tissue and cell lysates was evaluated with the BCA 
Protein Assay kit (Pierce Biotechnology, Rockford, USA) using bovine serum albumin (BSA, 
Sigma-Aldrich, Milano, Italy) as standard.  
 
9. Western blotting  
Aliquotes of 100 μg of protein were denatured by heating for 10 minutes at 70°C in 
NuPAGE® LDS Sample Buffer (4X) (Invitrogen), separated by NuPage Novex Bis-Tris 10% gels 
(Invitrogen, Life Technologies, Monza, Italy), and transferred onto nitrocellulose membranes 
(Invitrogen, Life Technologies, Monza, Italy) by electroblotting. Membranes were blocked in 
5% BSA in Tris-buffered saline (NaCl 5M, Tris-HCl 1M pH 7.4) containing 0.1% Tween 20 (TBS-
T) for 40 minutes and probed with 1:200 goat polyclonal anti-Hao2 antibody (sc-242990, 
Santa Cruz Biotechnology, Santa Cruz, CA) in 5% BSA, overnight at 4°C. Membranes were 
then incubated with 1:5000 anti-goat horseradish peroxidase (HRP) -secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) in 5% BSA for 90 minutes at room temperature. 
After three washes in TBST, proteins were revealed with the Super Signal West Pico (Pierce 
Chemical Co., New York, NY). Levels of Hao2 were normalized to the housekeeping gene 
anti-actin (A4700, Sigma-Aldrich, Milano, Italy) that was used also as loading control. 
 
10. Cell lines 
For all in vitro experiments 9 HCC human cell lines and cells isolated by a HCC bearing 
rat (R-H cells, Petrelli A et al, 2014) were used.  
HA22T/VGH, Hep3B, HepG2, HuH7, Mahlavu and Sk-Hep-1 were kindly provided by Dr. 
Silvia Giordano, IRCC Institute of Candiolo (Turin, Italy). In addition, SNU 182, SNU 398 and 
SNU 475 cells were kindly provided by Dr. Laura Gramantieri, St. Orsola-Malpighi University 
Hospital (Bologna, Italy). Cells were maintained at 37°C in a 5% CO2 humidified atmosphere. 
All culture medium and their constituents were purchased from Gibco (Life Technologies, 
Monza, Italy). 
HA22T/VGH cells were cultured in RPMI (Roswell Park Memorial Institute)-1640 
medium with 10% inactivated fetal bovine serum (FBS, Lonza, Basel, Switzerland), 1% 
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sodium pyruvate, and 1% penicillin-streptomycin. Serum was inactivated in water bath at 
56°C for 1 hour. 
Hep3B and Sk-Hep-1 were cultured in Minimum Essential Medium (MEM) with 10% 
FBS, 1% sodium pyruvate, 1% non-essential amino acids and 1% penicillin-streptomycin. 
HepG2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS, 1% glutamine and 1% Penicillin-Streptomycin. 
HuH7 and Mahlavu cells were cultured in DMEM supplemented with 10% inactivated 
FBS, 1% glutamine and 1% penicillin-streptomycin. 
SNU 182, SNU 398 and SNU 475 cells were cultured in RPMI-1640 medium with 10% 
FBS, 1% glutamine, and 1% penicillin-streptomycin. 
The R-H cells were obtained by classical collagenase perfusion techniques from HCC-
bearing rats subjected to the R-H protocol and sacrificed at 14 months. Cells were cultured in 
collagen-coated plates, in RPMI-1640 medium with 10% FBS (Petrelli A et al, 2014). 
 
10.1. Stable transduction with Hao2 
Human Embryonic Kidney 293 cells (HEK293T, ATCC, Manassas, VA, USA) were 
cultured in Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco, Life Technologies, Monza, 
Italy) with 10% FBS in a 5% CO2 atmosphere. The HAO2 construct (HsCD00439253) was 
purchased from DNASU plasmid repository of the Biodesign Institute, Arizona State 
University and cloned into pLX304 (Gateway V5-tagged lentiviral expression vector). 
Lentiviral vector for the constitutive expression of HAO2 was produced by transient 
transfection of the bidirectional transfer plasmid, the packaging plasmids pMDLg/pRRE and 
pRSV.REV, and the vesicular stomatitis virus (VSV) envelope plasmid pMD2.VSV-G (15, 6.5, 
2.5, and 3.5 μg, respectively, for 10-cm dishes) in HEK293T cells using the calcium phospate 
method (Chen CA et al, 1988). The virus containing medium was collected at 48h from 
transfection and used to transduce Mahlavu and R-H cells. Cells were transduced in six-well 
plates (105 per well) in 2 ml total medium in the presence of polybrene, an attachment 
factor to enhance virus-cell fusion. 
 
10.2. Crystal violet cell growth assay 
Both Mahlavu (500 cells/well) and R-H cells (1000 cells/well) and their Hao2 
transduced counterpart were seeded in 96-well plates. Cell growth was evaluated by crystal 
violet staining 96 hours, 6 days and 8 days after seeding. Cells were fixed with a solution of 
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22% glutaraldehyde in PBS at room temperature on a rotary shaker for 20 minutes and then 
washed with PBS. Cells were stained with a crystal violet solution at room temperature on a 
rotary shaker for 20 minutes, washed two times in PBS and in distilled water. After air-drying 
at room temperature, cells were dissolved in 10% acetic acid in distilled water for 20 minutes 
at room temperature on a rotary shaker. One-hundred µl of each sample were than 
transferred in a 96-well plate and optical density (OD) was measured at 590 nm (PerkinElmer 
2030 Software). 
 
10.3. Soft agar colony formation assay 
Anchorage-independent growth was determined by the colony formation assay in soft 
agar in wild type and Hao2 transduced, Mahlavu and R-H cells. It was performed in a 24 well 
plate embedding 3x103 cells/well in 0.5% SeaPlaque low melting agarose (BioWhittaker 
Molecular Applications-BMA, 50100) on top of a layer of growth medium containing 1% 
agar. The cell suspension was incubated in a humidified atmosphere in the presence of 5% 
CO2 at 37° C and, after 2 weeks, colonies were stained with crystal violet and quantified by 
counting all visible colonies. 
 
10.4. Rat Tumorigenicity Assay  
Wild type and stably transduced Hao2 R-H cells (106/rat) in 20% Matrigel Matrix (BD 
Biosciences, Milano, Italy) were injected subcutaneously in the right flank of F-344 syngeneic 
male rats (n=7 rats for wild-type and n=6 rats for transduced Hao2 R-H cells). Rats were 
monitored twice/week for monitoring tumor formation. 
 
11. Human samples 
Two cohorts of patients carrying HCC were examined. The first consisted of HCCs and 
matched non-neoplastic liver parenchyma obtained from 59 consecutive patients 
undergoing liver resection for HCC and 5 liver healthy donors. Specimens and clinico-
pathological data were obtained from the Institute of Pathology, University Hospital of Basel, 
Switzerland. All patients gave written informed content to the study, which was approved by 
the Ethics Committee of the University Hospital of Basel (EKKB). HCC diagnosis was verified 
by pathological examination, no anti-cancer treatments were given before biopsy collection. 
Tumor differentiation was defined according to Edmondson’s grading system. Only biopsies 
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containing at least 50% of tumor cells and no necrotic area have been used in this study. The 
clinico-pathologic features of patients are described in Table 1. 
 
 
Table 1. Clinicopathological Data of the HCC studied cohort from Institute of Pathology, 
University Hospital of Basel, Switzerland. 
 
As to the second set of patients, it consisted of HCCs and matched cirrothic tissues 
obtained from 59 consecutive patients (45 males and 14 females) undergoing liver resection 
for HCC at the Policlinico S. Orsola-Malpighi, Bologna, Italy. Eight normal liver tissues were 
obtained from patients undergoing liver surgery. No patient received anticancer treatment 
prior to surgery. The characteristics of patients are described in Table 2. 
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Table 2. Clinicopathological Data of the HCC studied cohort from the Policlinico S. Orsola-
Malpighi, Bologna. 
 
 
11.1. Microarray analysis 
Human microarray analysis was performed in collaboration with the University 
Hospital of Basel. RNA for the microarray was isolated for Transcriptomic profiling from 59 
HCC needle biopsies matched with their corresponding non-neoplastic liver parenchyma and 
5 normal liver donors with Direct-Zol RNA MiniPrep Kit (Zymo Research) including on-column 
DNAse treatment. RNA concentration was assessed using NanoDrop ND2000 (Nanodrop) 
and RNA integrity was monitored on Bioanalyzer 2100 using RNA6000 Chip (Agilent). 270 ng 
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of DNAse-treated total RNA was subjected to target synthesis using the WT Expression kit 
(Ambion) following standard recommendations. Fragmentation and labeling of amplified 
cDNA were performed using the WT Terminal Labeling Kit (Affymetrix). Synthesis reactions 
were carried out using a PCR machine (TProfessionnalTrio, Biometra) in 0.2ml tubes 
(Starlab). Eighty-five µl cocktail (23.4ng/µl labeled DNA) were loaded on GeneChip®Human 
Gene 1.0ST arrays (Affymetrix) and hybridized for 17 hours (45°C, 60rpm) in Hybridization 
oven 645 (Affymetrix). The arrays were washed and stained on Fluidics Stations 450 
(Affymetrix) by using the Hybridization Wash and Stain Kit (Affymetrix) under FS450_0002 
protocol. The GeneChips were scanned with an Affymetrix GeneChip Scanner 3000 7G. DAT 
images and CEL files of the microarrays were generated using Affymetrix GeneChip 
Command Control (version 4.0). Afterwards, CEL files were imported into Qlucore software 
and Robust Multichip Average (RMA) normalized. Subsequently, principal component 
analysis to discriminate between engineered and control cells will be performed. Quantile 
normalization and data processing were performed using the GeneSpringGXv11.5.1 software 
package (Agilent, USA). The gene signature value was assessed using the BRB-ArrayTool 
(v4.3.2, NIH).  
 
11.2. Tissue microarray (TMA) and immunohistochemistry 
For immunohistochemical analysis of HAO2, in collaboration with the University 
Hospital of Basel, we analysed formalin-fixed paraffin embedded (FFPE) tissue samples 
organized into a tissue microarray (TMA), as previously described (Baumhoer D et al, 2008). 
Briefly, this array contains 434 tissue specimens from both HCC and non-neoplastic liver 
tissue samples. Roughly 60% of used specimens used for the TMA construction were 
obtained from patients that underwent surgical resection without prior treatment for HCC, 
while the remaining were collected from autopsy cases. Histologic grading and classification 
of used liver samples was performed by 2 experienced pathologists according to the World 
Health Organization classification and Edmondson & Steiner grading system.  
Sections of 4 µm of paraffin embedded tissue were immunostained using a primary 
antibody against HAO2 (NBP2-32037 Novus Biologicals, Littleton, CO, USA). Automated IHC 
were carried out in the Ventana BenchMark (Ventana Medical Systems, Tucson, AZ, USA) 
platform by using the primary antibody against HAO2 diluted at 1:10. 
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12. Statistical analysis 
For qRT-PCR analysis, data are expressed as mean ± standard error (SEM). Analysis of 
significance was done by One-Way ANOVA, followed by Tukey-Kramer multiple-comparison 
post-hoc test and t Student’s test using the GraphPad software (La Jolla, California).  
Differences in patient survival were assessed using the Kaplan–Meier method and 
analysed using the log-rank test in univariate analysis. Cut-off scores were selected by 
evaluating the receiver-operating characteristic (ROC) curves. The point on the curve with 
the shortest distance to the coordinate (0, 1) was selected as the threshold value to classify 
cases as “positive/overexpressing” or “negative/down-regulated”. Analyses were performed 
using the SPSS (Statistical Package for Social Science) software (IBM, Armonk, NY).  
P-value were considered significant at p< 0.05. 
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RESULTS 
 
 
1. Analysis of Hao2 in rat preneoplastic lesions and HCCs 
Previous gene expression profiling performed in advanced HCCs generated by the 
Resistant Hepatocyte rat model, has shown that Hao2 was among the five mostly down-
regulated genes (Table 3, Petrelli A et al, 2014) 
 
Gene Full name 
Fold change 
aHCC/Control 
Cyp2c cytochrome P450, subfamily 2 - 69.57 
Obp3 alpha-2u globulin PGCL4 - 49.07 
Ca3 carbonic anhydrase 3 - 29.79 
Dhrs7 dehydrogenase/reductase (SDR family) member 7 - 22.80 
Hao2 hydroxyacid oxidase 2 - 10.86 
Cdh17 cadherin 17 - 10.80 
Olr59 olfactory receptor 59 - 9.86 
Avpr1a arginine vasopressin receptor 1A - 8.75 
 
Table 3. Most down-regulated genes in microdissected advanced HCCs (fold change versus 
controls <-5). Adapted from Petrelli A et al, 2014. 
 
 
Based on these preliminary data, we performed real time PCR to validate these results 
and, in particular, to investigate whether Hao2 down-regulation occurs also during early 
stages of liver carcinogenesis. To this aim, we laser-microdissected preneoplastic lesions 
identified, by their positivity to GSTP, and HCCs, generated at 10 weeks and 14 months after 
DENA treatment, respectively. 
As shown in Fig. 6, a significant reduction of the expression of Hao2 was observed in all 
GSTP+ preneoplastic nodules and HCCs, compared to normal liver samples. Hao2 mean 
expression in HCCs vs. preneoplastic lesions vs. control livers was: 0.06 ± 0.01 vs. 0.25 ± 0.06 
(p<0.05) vs. 1 ± 0.05 (p<0.001). 
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Fig. 6. Hao2 average mRNA expression in rat control livers (n=4), preneoplastic lesions (n=19) and 
HCCs (n=9), as assessed by quantitative real-time PCR using the 2-ddCt method and rat GAPDH as 
endogenous control. Each bar represents mean ± standard error (SEM), calculated as fold-change 
difference. Tukey-Kramer test: *** p<0.001; * p<0.05. 
 
 
In agreement with mRNA levels, western blot analysis showed a very low level of Hao2 
protein content in HCCs compared to normal livers (Fig.7). 
 
 
Fig. 7. Total liver tissue lysate of controls (n=2) and HCCs (n=7) were analysed by Western Blot. 
Protein loading for each sample was verified using anti-actin antibody. 
 
 
These results demonstrated that down-regulation of Hao2 occurs in early stages of 
carcinogenesis and is maintained all along the tumorigenic process.  
 
2. Hao2 is mostly down-regulated in the subset of nodules expressing the putative 
progenitor cell marker Krt-19 
The well-characterized Resistant Hepatocyte (RH) rat model allows to identify 
phenotypically distinct lesions along the various steps of carcinogenesis (early nodules, 
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adenomas, early HCC, and advanced HCC). These lesions can be classified according to their 
positivity to two well-known tumor markers, GSTP and Krt-19. At early stages (10 weeks 
after DENA initiation), two types of preneoplastic lesions are identified: persistent and 
remodeling nodules. While the former progress to HCC, the latter undergo re-differentiation 
to a mature phenotype that precedes their disappearance (Enomoto K et al, 1982). Our 
previous findings showed that remodelling nodules are characterized by a positive staining 
for GSTP, but not for Krt-19; on the opposite, persistent GSTP+/Krt-19+ nodules have been 
identified as the progenitors of HCC (Andersen JB et al, 2010). 
To investigate whether down-regulation of Hao2 is specific for the subset of Krt-19 
positive nodules or is common for all preneoplastic lesions, we laser-microdissected both 
Krt-19 positive and negative nodules and analysed Hao2 mRNA levels by qRT-PCR. The 
results showed that although a down-regulation of Hao2 occurred in both types of 
preneoplastic lesions (p<0.001), a significantly stronger decrease characterized Krt-19+ 
lesions (Fig. 8 A,B). Hao2 mean expression in Krt-19 positive vs. Krt-19 negative vs. control 
liver was: 0.08 ± 0.02 vs. 0.48 ± 0.09 vs. 1 ± 0.05. 
 
 
Fig. 8. QRT-PCR analysis of Hao2 mRNA expression levels in rat control livers (n=4), Krt-19- nodules 
(n=8) and Krt-19+nodules (n=11). (A) The levels of Hao2 were calculated as relative mRNA expression 
using the 2-ddCt method and rat GAPDH as endogenous control. (B) Average expression of Hao2 mRNA 
levels was reported as fold change differences between samples in panel A. Each bar represents 
mean ± standard error (SEM). Tukey-Kramer test: *** p<0.001. 
 
 
These data demonstrate that a sustained down-regulation of Hao2 characterized a 
subset of nodules expressing the progenitor cell marker Krt-19 and considered to be the 
precursor cell population of HCC. 
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3. Is Hao2 down-regulation a species-dependent event or a common feature of HCC? 
To determine whether down-regulation of Hao2 is species-dependent or a common 
event in hepatocarcinogenesis, we analysed by qRT-PCR the expression of Hao2 in a mouse 
model of liver carcinogenesis, consisting of a single injection of DENA followed by treatment 
with the CAR ligand TCPOBOP (once/week/28 weeks). TCPOBOP induces liver hyperplasia 
and hypertrophy (Dragani et al, 1985; Manenti et al, 1987), and promotes HCC development 
28 weeks after DENA administration (Kowalik MA et al, 2011). These results, similarly to 
those obtained in rats, showed a significantly down-regulation of Hao2 in mouse HCCs as 
compared to control liver (Fig. 9A,B). Hao2 mean expression in HCCs vs. control liver was: 
0.14 ± 0.01 vs. 1 ± 0.16 (p< 0.001). 
 
 
Fig. 9. QRT-PCR analysis of Hao2 mRNA expression in in matched-aged mice treated weekly only with 
TCPOBOP (n=3) and HCC (n=19) developed after 28 weeks of repeated doses of TCPOBOP following a 
single injection of DENA (A) The levels of Hao2 were calculated as relative mRNA expression using the 
2-ddCt method and mouse GAPDH as endogenous control. (B) Average expression of Hao2 mRNA 
levels was calculated as fold change of samples in panel A. Each bar represents mean ± standard 
error (SEM). Unpaired t-test: *** p<0.001. 
 
 
4. Down-regulation of Hao2 takes place also in HCCs generated in the absence of 
administration of genotoxic agents 
In both the previous models, initiation of the carcinogenic process is triggered by the 
genotoxic agent DENA. To explore the possibility that down-regulation of Hao2 could be the 
consequence of a direct interaction and DNA damage caused by DENA-derived metabolites, 
we used a mouse model in which HCC was generated following repeated doses of the non-
genotoxic agent TCPOBOP, in the absence of DENA pre-treatment.  
The results showed that HCCs developed in 100% of mice, although much later than in 
the DENA+TCPOBOP group (42 vs. 28 weeks, data not shown). As shown in Fig. 10 A,B, a 
40 
 
 
strong down-regulation of Hao2 was observed also in TCPOBOP-induced HCCs (Hao2 mean 
expression in HCCs vs. control liver was: 0.23 ± 0.04 vs. 1 ± 0.16; p<0.001). 
 
 
Fig. 10. QRT-PCR analysis of Hao2 mRNA expression levels in matched-aged mouse control livers 
(n=3) and HCC (n=11) generated by repeated injections of TCPOBOP for 42 weeks. (A) The levels of 
Hao2 were calculated as relative mRNA expression using the 2-ddCt method and mouse GAPDH as 
endogenous control. (B) Average expression of Hao2 mRNA levels was calculated as fold change of 
samples in panel A. Each bar represents mean ± standard error (SEM). Unpaired t-test: *** p<0.001. 
 
 
The finding that a strongly down-regulation of Hao2 is observed in both mouse 
models, with or without the genotoxic agent DENA, demonstrates that the dysregulation of 
this gene is not only species- but also etiology-independent. 
 
5. The role of Hao2 in proliferation of normal hepatocytes 
Since preneoplastic and neoplastic lesions exhibit a higher proliferation rate compared 
with adult quiescent liver, we wished to investigate whether the expression of Hao2 is linked 
to the proliferative status of hepatocytes. To this aim, we determined Hao2 expression in 
normal rat hepatocytes during liver regeneration following 2/3 partial hepatectomy. QRT-
PCR analysis showed a highly significant down-regulation of Hao2 after 24 and 48 hours of 
surgery, a time corresponding to the peak of S phase, with a trend towards control levels at 
168 hours, a time when organ regeneration is almost completed (Fig. 11 A,B). (Hao2 mean 
expression 168h vs. 48h vs.24h after PH vs. control liver was: 0.37 ± 0.11 vs. 0.11 ± 0.02 vs. 
0.14 ± 0.02 vs. 1 ± 0.06). 
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Fig. 11. QRT-PCR analysis of Hao2 mRNA expression levels in rat control livers (n=3) and in animals 
subjected to 2/3 PH and sacrificed at 24 (n=4), 48 (n=4), and 168 hours (n=4) afterwards. (A) The 
levels of Hao2 were calculated as relative mRNA expression using the 2-ddCt method and rat GAPDH as 
endogenous control. (B) The average level of samples in panel A was calculated as fold change. Each 
bar represents mean ± standard (SEM). Tukey-Kramer test: *** p<0.001, * p<0.05, ns: not significant. 
 
 
These data show that Hao2 is down-regulated also during the active proliferation of 
normal hepatocytes and suggest a possible involvement of Hao2 in the entry of hepatocytes 
into the cell cycle. 
 
6. HAO2 expression is strongly down-regulated in human HCC 
In order to investigate whether the results obtained in rat and mouse experimental 
protocols of hepatocarcinogenesis could be of translational value for human HCC, we 
performed microarray analysis in 59 patients carrying HCC and subjected to liver biopsy 
matched with their corresponding non-neoplastic liver parenchyma and in 5 healthy liver 
donors (Clinicopathological data are summarized in Table 1). As shown in Fig. 12, down-
regulation of HAO2 occurred in all HCCs compared to healthy liver donors. Additionally, 
samples matched analysis (tumor vs. non cancerous cirrhotic tissue) revealed a down-
regulation of HAO2 in 84.7% of HCCs (50 out of 59 tumors). 
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Fig. 12 HAO2 expression levels in non neoplastic liver samples (n=5) and HCC specimens (n=59) 
compared to their matched non tumoral counterpart. HAO2 mRNA expression is assessed by 
Affimetrix microarray and measured as probe intensity levels. Paired Student t-test: tumoral vs. non 
tumoral area p<0.05. 
 
 
Furthermore, we analysed expression levels of HAO2 in patients classified according to 
the Edmondson and Steiner (ES) grading system and their aetiology. Low expression of Hao2 
was significantly observed in high-grade (III-IV) vs. low-grade (I-II) HCCs ,Fig. 13A, but not in 
association with different aetiological agents (Fig. 13B). 
 
 
Fig.13 Stratification of patients in according to (A) the Edmondson and Steiner (ES) grading system 
and (B) the aetiological related agent. HAO2 mRNA expression is assessed by Affimetrix microarray 
and measured as probe intensity levels. Unpaired Student t-test: low (I-II) vs. high grade (III-IV) 
p<0.05. 
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Finally, to explore whether HAO2 expression is associated with clinical progression and 
outcome of HCC patients, we examined the incidence of metastases and patient overall 
survival (OS) rates using Kaplan-Meier analysis. The metastatic status was defined as either 
regional lymph node invasion and/or distant organ involvement. Patients with low HAO2 
expression showed an increased metastatic activity (Fig. 14A) and a decreased OS (median 
of 10 versus 31 months in low vs. high HAO2, respectively; Fig. 14B).  
 
 
Fig. 14 HAO2 expression levels, analysed by Affimetrix microarray and measured as probe intensity 
levels, in association with (A) metastasis formation and (B) predicts poor pantients survival. Survival 
plot was analysed using the Kaplan-Meier method. ROC analysis was used to discriminate between 
high and low expressing levels of HAO2. Unpaired Student t-test: all P values <0.05. 
 
 
Next, we investigated the expression levels of Hao2 in another distinct series of 59 
human HCCs and their corresponding peritumoural tissues provided by the Policlinico S. 
Orsola-Malpighi of Bologna. The characteristics of the study population are described in 
Table 2. Similarly to what observed in the previous cohort, HCC down-regulation was 
confirmed in all samples compared to normal liver donors (Fig. 15A,B) and in 88.1 % of 
samples compared to matched cirrhotic tissues (52 out of 59 tumors ,Fig. 15A,B).  
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Fig. 15 QRT-PCR analysis of Hao2 mRNA expression levels in human HCCs and matched cirrhotic 
tissues (n=59) and in normal liver (n=8). (A) The levels of Hao2 were calculated as relative mRNA 
expression using the 2-ddCt method and represented as log 2. Human β-actin was used as endogenous 
control. (B) The average levels of samples in panel A were calculated as fold change. Each bar 
represents mean ± standard error (SEM). Tukey-Kramer test: ** p<0.01,*** p<0.001. 
 
 
Altogether these data show that in humans, as well as in rodents, HAO2 mRNA levels 
are significantly down-regulated in HCC development. 
 
7. HAO2 protein content is decresed in human HCC 
We next evaluated the content of HAO2 protein in human HCC. Initially, we performed 
immunohistochemical staining (IHC) for HAO2 in tissue specimens from both HCC and non-
neoplastic liver tissue samples from patients of the Basel cohort. Initial studies were 
performed to find the most appropriate antibody for IHC staining. From our search, while 
antibodies for western blot were provided by different companies, only the Novus 
Biologicals antibody was recommended for HAO2 staining in human tissues. Using this 
antibody, we found positivity for HAO2 in human cirrhotic areas (Fig. 16A) which was 
reduced in most of human HCCs (Fig. 16B,C). In addition tissue microarray (TMA) staining 
showed (Fig. 16D) that approximately 60% of HCC analysed exhibited a reduced HAO2 
staining when compared to surrounding liver (Fig. 16D,E). 
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Fig. 16. Representative pictures of HAO2 immunohistochemical in HCC and non-neoplastic liver 
tissue samples. HAO2 protein levels analised by IHC staining in (A) cirrhotic liver at 100x 
magnification and in HCC samples (B) at 100x (C) and 200x magnification. TMA staining in non-
neoplastic liver tissue (D) and HCC punches (E) at 100x magnification. 
 
 
Although the results of IHC were encouraging, we were not completely satisfied by the 
immunostaining of liver samples. Therefore, we performed western blot analysis in 7 human 
HCCs and their cirrhotic counterparts. As shown in Fig. 17, HAO2 protein content was 
strongly decreased in 5/7 HCCs, when compared to their corresponding cirrhotic 
peritumorural livers. 
 
 
 
Fig. 17. HAO2 expression levels analysed by western blot in 7 HCCs and their cirrhotic 
peritumoral livers (PT). Actin antibody was used as an internal control. 
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These results clearly show that HAO2 is down-regulated at both mRNA and protein 
levels in human HCC. 
 
8. HAO2 in vitro and in vivo 
To better understand the biological role of HAO2, we decided to investigate the 
expression levels of Hao2 in 7 HCC human cell lines: HA22T, HepG2, HuH7, Mahlavu, SNU 
182, SNU 398, SNU 475. QRT-PCR showed that Hao2 was expressed at very low levels in all 
cell lines analysed (ΔCt ranging from 32-34 in HuH7 and HepG2, to 37-39 in all other cell 
lines, Fig. 18). The results were quantified as Ct ( threshold cycle) values, defined as the cycle 
number of PCR at which the amplified product is first detected; Ct value is inversely related 
to the starting amount of target. Similarly, low Hao2 mRNA expression levels was found in R-
H rat liver cells, obtained from HCC bearing rats (Petrelli A et al, 2014). 
 
 
Fig. 18. QRT-PCR analysis of HAO2 mRNA expression levels in 7 human HCC cell lines, HA22T, HepG2, 
HuH7, Mahlavu, SNU-182, SNU-398, SNU-475. The levels of Hao2 were indicated as Ct value using 
human beta-actin as endogenous control. 
 
 
Accordingly, no detectable signal was detected by western blot analysis in all 7 HCC 
cell lines (Fig. 19). 
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Fig. 19. Western blot analysis of HAO2 in human and R-H cell lines. HAO2-transduced Mahlavu 
(HAO2-Mahlavu) and R-H cell lines (HAO2-R-H) were used as positive controls.  
 
 
Therefore, the down-regulation of Hao2 was confirmed also in human HCC cell lines at 
both mRNA and protein levels. 
In order to investigate whether an increase in HAO2 expression could hamper cell 
growth, we performed soft agar and cell growth assays in human Mahlavu and rat R-H cell 
lines transduced with a lentiviral construct containing HAO2; we did not observe significant 
alteration in anchorage-dependent or independent growth ability between human and rat 
cell lines compared to their transduced counterparts (data not shown). 
Moreover, we tested in vivo if the increase of Hao2 expression could impact the 
tumorigenic ability of Hao2-transduced cells. Therefore, parental and Hao2-transduced R-H 
cell lines were subcutaneously grafted into syngeneic F-344 rats. We found that while 
parental R-H cells were able to form tumors in 3/7 animals, no tumors was observed in all 6 
rats grafted with Hao2-transduced cell lines within 40 days post injection (Fig. 20). 
 
48 
 
 
 
Fig. 20. Photograph of rats 40 days after the injection of wild type (right) or Hao2-transduced 
(left) R-H cancer cells. Cells were subcutaneously injected into the right posterior flanks of 
syngeneic male Fischer F-344 rats. Tumor is shown by the arrow. 
 
 
This data suggest that down-regulation of Hao2 could effectively support tumor 
growth. 
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DISCUSSION 
 
 
L-2 Hydroxy acid oxidases are flavin mononucleotide (FMN)-dependent peroxisomal 
enzymes which are able to oxidize a number of 2-hydroxy acids to 2-keto acids resulting in 
hydrogen peroxide formation at the expense of molecular oxygen (Angermüller S. 1989; Fry 
DW et al, 1979; Schwam H et al, 1979).  
Currently, very few data are available in literature about hydroxy acid oxidases and 
their functional role remains to be defined. Some authors reported an involvement of these 
enzymes in fatty acid α-oxidation (Jones JM et al, 2000) or in regulation in blood pressure 
(Lee SJ et al, 2003; Rico-Sanz J et al, 2004), albeit the mechanisms are not fully explained. By 
producing hydrogen peroxide, during their enzymatic activity, hydroxy acid oxidases might 
contribute to generate oxidative stress, by increasing ROS levels. High ROS levels are 
associated with cell death and cellular damage and with an abnormal cancer cell growth 
(Toyokuni S et al, 1995). 
Unfortunately, the role of Hao2, if any, in cancer is still unknown. Indeed, the only 
study associating Hao2 and cancer was a study of gene expression profile in human 
intrahepatic cholangiocarcinomas. This study identified Hao2 among down-regulated genes 
in these tumors (Wand AG et al, 2006), but no comments or hypotheses about its role were 
proposed by the authors.  
To our knowledge, the results obtained in my thesis are the first to show that Hao2 is 
profoundly down-regulated in HCCs. The main findings stemming from our study can be 
summarised as follows: i) Hao2 is down-regulated in 100% of rat and mouse HCCs and in 
about 80% of human HCCs; ii) Hao2 down-regulation is species and etiology independent; iii) 
Hao2 down-regulation is a very early event in multistage hepatocarcinogenesis; iv) it is more 
pronounced in the most aggressive preneoplastic lesions; v) its levels are inversely 
correlated with overall survival and metastasis; vi) transduction of Hao2 inhibits the 
tumorigenic potency of HCC cells in vivo. 
At the present, no data are available to explain the reduced expression of Hao2 
observed in HCC. Several epigenetic or genetic alterations or post-transcriptional regulation, 
such as that caused by miRNA could be involved. Searching for Hao2-targeting miRs, we 
found that miR-183 is predicted to bind to complementary sequences located in the 3′-
untranslated (3‘-UTR) region of Hao2 mRNA. Previous work done in our laboratory has 
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shown that this miR is up-regulated in Krt-19 positive preneoplastic lesions (75-fold) and in 
HCCs (15-fold) developed with the R-H model of hepatocarcinogenesis (Petrelli A et al, 
2014). Notably, the same lesions exhibited Hao2 down-regulation, when compared to 
control liver, suggesting that increased levels of miR-183 could be responsible for Hao2 
down-regulation. Further studies will be performed to establish if this or other miRs are 
indeed responsible for Hao2 down-regulation in the carcinogenic process. 
Although the mechanisms underlying Hao2 decrease in pre- and neoplastic lesions are 
unclear, it is possible to speculate that this enzyme plays a role in hepatocyte proliferation 
and survival. Indeed, the findings that i) the expression levels of Hao2 decreased during liver 
regeneration after PH, and that, ii) the maximal Hao2 down-regulation occurs in the most 
aggressive rat preneoplastic lesions (Krt-19+), which proliferate at a higher rate than those 
negative for this marker (Petrelli A et al, 2014), suggest that Hao2 is inversely correlated to 
cell cycle, in a way resembling tumor suppressor genes.  
Another possible explanation for the biological effect driven by decreased levels of 
Hao2 could be linked to the ability of this enzyme to produce hydrogen peroxide. Loss of this 
enzyme may represent a cytoprotective mechanism by which genetically-altered cells can 
escape excessive ROS generation and cell damage/death.  
Independently upon the mechanism through which Hao2 regulates hepatocyte behaviour, 
our findings can have a relevant translational value in terms of both prognosis and diagnosis.  
Indeed, the novel finding that Hao2 expression is virtually absent in preneoplastic lesions, 
suggests its possible use as a diagnostic marker. This possibility is supported by our 
preliminary findings showing immunohistochemical positivity for HAO2 in human cirrhotic 
areas, but not in most of human HCC. It is possible to hypothesize that HAO2 staining might 
allow early identification of dysplastic nodules and their discrimination from cirrhotic 
regenerative nodules, a diagnosis that is presently problematic in most circumstances.  
HAO2 can also be useful for prognostic purposes. Indeed, as shown in my thesis, the 
levels of HAO2 in HCC inversely correlate with increased metastatic ability of the tumor and 
overall survival of the patients. 
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